Latest Medical Devices News
Astro-Med Posts Net Sales Of $14.6 Million For Q1 Fiscal 2010
Astro-Med, Inc. (Astro-Med) has reported net sales of $14.6 million for the first quarter of fiscal 2010, compared with the net sales of $18.6 million in the year-ago quarter. It also reported a net loss of $0.23 million, or $0.03 loss per diluted share, for the first quarter of fiscal 2010, compared with the net income of $0.89 million, or $0.12 per diluted share, in the year-ago quarter.
Published: 19-May-2009
OrthoMEMS And MEMSCAP Announces Partnership And Development Agreement For Biomedical Sensor
MEMSCAP and OrthoMEMS announced a multi-year strategic partnership and development agreement to manufacture an innovative MEMS sensor for the assessment and treatment of mechanical low back pain. Financial terms of the agreement were not disclosed.
Published: 19-May-2009
L&K Announces Investigation Against VNUS
The law firm of Levi & Korsinsky LLP (L&K) announced an investigation into the circumstances surrounding the acquisition of VNUS Medical Technologies, Inc. (VNUS). L&K is investigating potential claims against the board of directors of VNUS, concerning possible breaches of their duties and other violations of law related to their agreement to sell the company to Covidien Ltd for $29 per share.
Published: 19-May-2009
Cordis’ Nevo Sirolimus-Eluting Coronary Stent Shows Superior Results In Comparison To Taxus Liberte Stent
At six months, the NEVO Sirolimus-eluting Coronary Stent, incorporating RES Technology, was superior to the Taxus Liberte Stent in reducing tissue growth within the stent that can potentially lead to repeat procedures, in new clinical study results released. In addition, no reports of stent thrombosis were reported in patients treated with NEVO through six months.
Published: 19-May-2009
Medtronic To Reduce Global Workforce
Medtronic, Inc. (Medtronic) plans to reduce its global workforce by 1,500 to 1,800 employees, in an effort to streamline operations and to further align the company with its long-term growth outlook. This reduction includes about 400 US employees who have accepted early retirement or voluntary separation agreements and who will complete their employment with the company by May 29, 2009. The company expects the majority of the reduction to be completed by June 30, 2009.
Published: 19-May-2009
Cordis Presents Results Of Cypher Sirolimus-Eluting Coronary Stent During Late Breaking Clinical Trials At EuroPCR
Four-year results of a large, multi-center clinical trial show that earlier results favoring the CYPHER Sirolimus-eluting Coronary Stent over bare metal stents (BMS) in patients with acute myocardial infarction (heart attack) were maintained in long-term follow-up. In addition, there were no differences in key safety measures between the CYPHER Stent and BMS.
Published: 19-May-2009
Cardiva Medical Announces FDA Approval For Catalyst III System
Cardiva Medical, Inc. announced that it has received clearance from the US Food & Drug Administration (FDA) for its latest technology, the Cardiva Catalyst III, which is considered the first drug coated vessel closure device in the market.
Published: 19-May-2009
InfraReDx ‘s Combined Near-Infrared Spectroscopy And Ultrasound Imaging Catheter First Uses In Coronary Patients
InfraReDx, Inc. announced the first use in patients of a novel coronary catheter that uses both light and sound to image coronary plaques. Working on a team led by Dr. Patrick Serruys, Dr. Martin van der Ent performed the procedures on May 11, 2009 in patients undergoing coronary angiography at the Thoraxcenter.
Published: 19-May-2009
Medtronic’s Endeavor Drug-Eluting Stent Receives CE Mark Approval For Treating Acute Coronary Syndrome
Medtronic announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE Mark approval for treating patients with acute coronary syndrome (ACS).
Published: 19-May-2009
Boston Scientific Announces Launch Of Third-Generation Platinum Chromium Drug-Eluting Stent In Select Markets
Boston Scientific Corporation announced the launch of the platinum chromium TAXUS Element Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The TAXUS Element Stent features a new platinum chromium alloy engineered specifically for coronary stent applications and represents the Company's third-generation drug-eluting stent (DES) technology.
Published: 19-May-2009
